There are many parallels between human and equine sports medicine, including the roots of athletics, the development of specialized medicine, and injuries to the athletes. The most remarkable similarities are seen in tendinopathies. Because of the similarities between human and equine tendons, equine athletes serve as one of the best animal models to study tendon physiology and tendon injuries for application to human medicine. Because of this, many therapies have already successfully crossed from one realm of sports medicine to the other, the most notable of which are stem cell therapy, Interleukin-1 Receptor Antagonist (IRAP), and platelet rich plasma (PRP) therapies. There are also several therapies on the horizon that are very promising to potentially be successful in both human and equine athletes. However, some of these novel therapies are raising ethical questions. There are many regulations in place to protect against or address potential ethical conflicts in human medicine. The same trend is not seen in equine medicine. While there are rules enforced by many equestrian federations regarding ethical concerns and veterinary medicine, the information is not nearly as complete as it should be. Because they lack the autonomy that typical human patient possesses, equine athletes require significantly more advocacy from their veterinarians than human athletes do from their physicians. Additionally, there is a lack of large animal model studies secondary to cost and overall value of equine athletes to their owners, riders, and trainers. Ultimately it becomes an issue of veterinary ethics whether to pursue a novel or conventional treatment for an equine athlete. With biotechnology advancing as quickly as it is, new studies must be done and new regulations must be written in order to keep all fields of sports medicine operating safely and ethically for all athletes involved, regardless of species.